Bioasis Technologies Inc.
BTI
Pozycja w akcjach
#39864
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Cena akcji
$0.00366968
Ostatnia synchronizacja: 2024-07-23
Kapitalizacja rynkowa
$291.42K
Zmiana (1 dzień)
-0.81%
Zmiana (1 rok)
1,734.84%
Kraj
US
Handel Bioasis Technologies Inc. (BTI)
Kategoria
Healthcare
Kapitalizacja rynkowa Bioasis Technologies Inc.(BTI)
Kapitalizacja rynkowa: $291.42K
Na dzień October 2026 spółka Bioasis Technologies Inc. ma kapitalizację rynkową wynoszącą $291.42K. Według naszych danych, czyni to Bioasis Technologies Inc. 39864th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej Bioasis Technologies Inc. od 2010 do 2026
BTI w porównaniu do 5 najpopularniejszych stocks
| Cena za BTI | Aktywa B | Kapitalizacja rynkowa B | Wyniki | |
|---|---|---|---|---|
$65,067.88
$7.94K
|
$5.167T | +65,067,875,482.42% | ||
|
$63,150.47
$7.94K
|
$5.015T | +63,150,474,156.39% | ||
|
$51,736.59
$7.94K
|
$4.108T | +51,736,585,054.77% | ||
|
$49,136.18
$7.94K
|
$3.902T | +49,136,176,181.32% | ||
|
$33,867.98
$7.94K
|
$2.689T | +33,867,976,754.30% |
